检索结果-南通市图书馆

The Administration of Ocoxin Increases the Quality of Life of Patients with Advanced Epithelial or Metastatic Ovarian Cancer Undergoing Neoadjuvant Chemotherapy

引用

Journal of Cancer Therapy 2022年第9期13卷 561-584页

作者： Karen López Miguel Daniel Ricardo Martínez Ávila Lliset Álvarez Pérez Gisselle Martínez Rabasa Alejandro Linchenat Lambert Roberto Esperón Noa Lisandra Heredia Manzano Margarita De Quesada Amigó Rafael I. Reyes Velázquez Danay Corrales Otero Ramon Ropero Toirac Idelmis Curbelo Heredia Mircea Betancourt Cabeza Tania A. Agrelo Ramos Rosa María Muñoz Reyes Juan Jesús Lence Anta Rosalía Fuentes Sosa Karelia Silvera Candó kirenia silva rodríguez Zaida Lastre Sosa Mayte Robaina García Eduardo Sanz David Marquez Department of Medical Oncology INOR La Habana Cuba Department of Gynaeco-Oncology INOR La Habana Cuba Department of Anatomical Pathology INOR La Habana Cuba Department of Imaging INOR La Habana Cuba Clinical Research Section INOR La Habana Cuba Department of Onco-Psychology INOR La Habana Cuba Clinical Laboratory Department INOR La Habana Cuba Clinical Trials Pharmacy Department INOR La Habana Cuba Department of Biostatistics CENCEC La Habana Cuba Scientific Department CATALYSIS Madrid Spain

Background: 70% of ovarian cancer cases are diagnosed at an advanced stage (III or IV) of the disease and, in turn, with a high prevalence of peritoneal carcinosis and ascites, which leads to progressive malnutrition in patients, with the consequent deterioration of their general condition. There is a very important relationship between nutritional status, quality of life, survival, and the ability to tolerate multidisciplinary treatment of peritoneal carcinosis. Methods: A phase II, open-label, single-center, non-randomised clinical trial was conducted that included 36 patients with advanced disease who were administered the nutritional supplement Ocoxin, 30 ml twice a day, beginning one week before chemotherapy (CT) based on carboplatin/paclitaxel, of which they receive three cycles with neoadjuvant intent. Ocoxin treatment was continued during chemotherapy and for three weeks after completion of the last cycle, as well as during any periods for which this treatment was discontinued due to toxicity. The effect of Ocoxin on the quality of life was assessed through the QLQ C30 and QLQ OV28 questionnaires from the start of treatment until the end of the follow-up period. In addition, the Karnofsky Index and nutritional parameters were assessed. Results: There were no significant differences between adverse events versus baseline values, except in leukocytes, lymphocytes, neutrophils, ALT, and AST. There was no deterioration of the QoL scales, except for those related to the effects of chemotherapy and alopecia. Conclusions: Ocoxin as an adjuvant to chemotherapy appears to improve better tolerance to chemotherapy, showed a good safety profile, and improved quality of life. For further information on Ocoxin neoadjuvant therapy benefits, a phase III clinical trial will be needed.

关键词： Chemotherapy Radiotherapy Ovarian Cancer Oncology Quality of Life Ad-juvant Therapy Supportive Care

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Specific Immunotherapy in Advanced Cervical-Uterine Cancer Using Humanized Monoclonal Antibody Nimotuzumab and CIMAvax-EGF<sup>®</sup>Therapeutic Vaccine

引用

Journal of Cancer Therapy 2021年第3期12卷 146-156页

作者： Raiza Ruiz-Lorente Sayly Alfonso Eduardo Santiesteban Yamilka Sánchez kirenia Camacho Erasmo Mendoza Carmen Elena Viada Ramón Ortiz Ihosvannys Carreño Mayelin Troche Meylan Cepeda Ana Rosa Vals Leticia Cabrera Annia Gorte Delmis Batista Milagros Domenech Yanela Santiesteban Yuliannis Santiesteban Daymys Estevez Jessica García-Viamontes Conrado Ramos Mico Mayra Ramos-Suzarte González Coro Hospital La Habana Cuba Celestino Hernández Robau Hospital Villa Clara Cuba Jose Ramón Lopez Tabranes Hospital Matanzas Cuba III Congreso Hospital Pinar del Río Cuba Faustino Perez Hospital Matanzas Cuba Center of Molecular Immunology Havana Cuba

Cervical uterine cancer represents the fourth most common malignant neoplasm worldwide in the female sex in terms of incidence, principally from epithelial origen. The high expression of EGFR in this tumor leads to the search for therapeutic alternatives. An Expanded Access Clinical Program was carried out in parallel groups, randomized, multicenter and prospective study, to evaluate the survival of patients with advanced cervical carcinoma, without therapeutic alternative, who would be treated with the therapeutic vaccine CIMAvax-EGF®, the humanized mAb nimotuzumab or the combination of both products, which targeted EGF and EGFR respectively. The patients were included between 2008 and 2010 with a more than five years follow-up. The results show that the serious adverse events related to the experimental treatments were 0.9%;1.1% and 2.6% and a medi

关键词： CIMAvax-EGF® Nimotuzumab Survival Safety Advanced Cervical Cancer

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：